• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
LeadershipOn Leading

CVS Health Leads Opioid Prescription Limitations as Trump Declares Public Health Emergency

By
Susie Gharib
Susie Gharib
Down Arrow Button Icon
By
Susie Gharib
Susie Gharib
Down Arrow Button Icon
October 26, 2017, 5:47 PM ET

President Donald Trump on Thursday declared the nation’s opioid epidemic a “public health emergency.” He also singled out CVS Health for its leadership in limiting opioid prescriptions to a seven-day supply compared to as much as 20 days.

In September, CVS was the first national retail chain to restrict how many pain pills doctors can give patients. CEO Larry Merlo tells Fortune the reaction from patients, physicians, and pharmacies has been “extremely positive.”

“We need to do our part to begin to reverse this trend that we’ve seen emerging for many years,” says Merlo.

CVS has the influence to be an important player in coming up with solutions. It manages medications for nearly 90 million customers at 9,700 retail locations. With revenues of $177 billion, it is ranked number seven on Fortune’s list of the 500 largest companies in the United States. It is bigger than General Motors and AT&T.

But not far behind CVS is Amazon, which reportedly may get into the pharmacy business by selling drugs online. A decision could come before the end of the year. What could this mean for CVS? Merlo does not appear concerned.

“We shouldn’t think of pharmacy as if we’re buying a book or a television,” he says, adding that the pharmacist at the neighborhood CVS store is the “frontline of healthcare.” Merlo also says, “Certainly if Amazon or any other competitor decided to enter that space, I’m confident that as our business continues to evolve, we’ll continue to be an effective competitor.”

Watch the video above to hear more of our conversation with Merlo.

About the Author
By Susie Gharib
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.